Research
Hormonal
Dual GLP-1/Glucagon agonists (e.g., mazdutide, cotadutide, efinopegdutide) show promise for treating non-alcoholic steatohepatitis (NASH) and obesity, though with higher rates of gastrointestinal side effects compared to GLP-1 monotherapy.
For patients with obesity and non-alcoholic steatohepatitis (NASH), dual GLP-1/Glucagon agonists may offer a unique benefit by promoting liver fat oxidation. However, these drugs may cause more gastrointestinal side effects than standard GLP-1 drugs, so the trade-off between liver benefits and tolerability should be discussed with a doctor.
ModerateQualifiesMEDIUM confidence
A niche for this drug may prove to be the treatment of non-alcoholic steatohepatitis, as the effects of GCG agonist on hepatic fat oxidation would be desirable in this group... however, nausea and vomiting were higher with efinopegdutide.
Why this rating
Based on Phase I/II trials and preclinical models; less mature data than tirzepatide.
Source
Harnessing the Incretin System with Multi-Agonists
Martin Whyte et al. · EMJ Innovation · 2022
DOI 10.33590/emjinnov/10115628
narrative_reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dual incretin agonists (specifically GIP/GLP-1 co-agonists like tirzepatide) produce significantly greater weight loss and glycemic reduction than single GLP-1 receptor agonists, effectively closing the treatment gap between pharmacotherapy and bariatric surgery.Good
- GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) and renal events compared to placebo, demonstrating cardiovascular and renal benefits beyond glycemic control.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →